Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FL-091 (Full-Life Technologies, df92e1)
- Development stage
- Preclinical
- Lead developer
- Full-Life Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FL-091 is a preclinical **radionuclide drug conjugate (RDC)** developed by **Full Life Technologies**. It is designed to target **B7-H3** (also known as **CD276**), an immune checkpoint protein that is significantly overexpressed in various aggressive cancers, including **small cell lung cancer (SCLC)** and **colorectal cancer (CRC)**, while maintaining low expression in healthy tissues. FL-091 consists of a high-affinity targeting moiety conjugated to the potent alpha-emitting radioisotope **Actinium-225 (225Ac)**. Upon binding to B7-H3 on the surface of tumor cells, the conjugate is internalized, allowing the alpha radiation to induce complex double-strand DNA breaks, leading to cell death. This targeted alpha therapy (TAT) approach aims to provide high therapeutic efficacy with minimal off-target toxicity.
- Other names
- B7-H3-RDCB-7-H3-RDCB 7-H3-RDCActinium-225-B7-H3 RDCActinium225-B7-H3 RDCActinium 225-B7-H3 RDC
02
Targets
NTR1 (Nitroreductase-1)
Beyond the preview
Go deeper on FL-091 (Full-Life Technologies, df92e1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FL-091 (Full-Life Technologies, df92e1).